This event is not part of the official Internal Medicine Meeting 2025 Education Program. CME credit is provided by organizations other than ACP.
Tuesday April 1, 2025
12:00 PM – 12:15 PM Registration/Lunch
12:15 PM – 1:15 PM Symposium
New Orleans Ernst N. Morial Convention Center
Meeting Room: 293-296 (Level 2)
900 Convention Center Blvd
New Orleans, LA
PROGRAM FEATURES
-
- Interactive case-based presentations and discussions
- Online personalized quality-improvement poster-generation portal
PRESENTING FACULTY
 |
Jay H. Shubrook, DO, FAAFP, FACOFP Professor and Diabetologist Department of Clinical Sciences and Community Health Touro University California Vallejo, CA |
 |
Chuck Vega, MD, FAAFP Health Sciences Clinical Professor UC Irvine Department of Family Medicine Irvine, CA |
PROGRAM OVERVIEW
This live activity has been designed to support primary care clinicians in improving the care of patients with early-stage type 1 diabetes (T1D). This includes proper screening for early detection, determining next steps for monitoring and follow-up, as well as coordination and referral for disease-modifying therapy. Primary care clinicians play a crucial role in the evolving landscape of early-stage T1D, and this program will provide important clinical pearls through interactive discussions, engaging animations, and actionable tools and resources for optimal multidisciplinary treatment of early-stage T1D.
TARGET AUDIENCE
This activity is designed to meet the educational needs of clinicians who treat or refer patients with or at high risk for T1D, including primary care clinicians and other allied healthcare professionals.
LEARNING OBJECTIVES
Upon completion of this activity, attendees will have improved ability to:
- Identify criteria for T1D screening, focusing on high-risk patients to facilitate timely referral and monitoring
- Develop workflows to appropriately monitor, follow-up, or refer individuals who are screened for T1D.
- Interpret T1D screening results and effectively communicate next steps to support patient education and inform treatment decisions
- Develop strategies for establishing referral pathways and enhancing collaboration with specialists in order to enable earlier application of disease-modifying therapies for early stage T1D
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hours.
COMMISSION ON DIETETIC REGISTRATION (CDR) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.0 CPEU.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event Staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group prior to the live event at [email protected]
